Tozorakimab
Tozorakimab Basic information
- Product Name:
- Tozorakimab
- Synonyms:
-
- Tozorakimab
- Research Grade Tozorakimab (DHB74004)
- Research Grade Tozorakimab
- Tozorakimab (anti-IL-33)
- CAS:
- 2376858-66-9
- MW:
- 0
- Mol File:
- Mol File
Tozorakimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Tozorakimab Usage And Synthesis
Uses
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease[1].
in vivo
Tozorakimab (0.1-10 mg/kg, i.p., once time) inhibits IL-5 levels in bronchoalveolar lavage fluid of humanized IL-33 genetically modified mice in dose-dependent manner[2].
References
[1] Reid F, et al. Safety, pharmacokinetics and immunogenicity of the anti-interleukin-33 antibody, tozorakimab: results of a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease. American Thoracic Society. 2022: A2398-A2398.
[2] England E, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13(1):9825. DOI:10.1038/s41598-023-36642-y
TozorakimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com